Press Releases Search View

Select Category

Recent News

Search By:

Search By Release Date

100 Record(s) Found. Displaying Page 5:

[<< Prev] 1 2 3 4 5

LabNow Inc. raises $605K
Print \| More options ▼ View RSS Feed
Release Date: 12-May-10 Author or Contact:
Biotechnology developer LabNow Inc. has received $605,000 of a planned $850,000 round of financing. Austin-based LabNow, which develops devices that test the white blood cell count of HIV patients, received the funding from five investors, according to a Tuesday filing with the U.S. Securities and Exchange Commission. The filing is listed as an amendment to a sale that initially happened in November 2009. In December 2009, LabNow ...
Click to read LabNow Inc. raises $605K

PLx Pharma gets $2M in NIH grants
Print \| More options ▼ View RSS Feed
Release Date: 12-May-10 Author or Contact:
PLx Pharma Inc. has received $2 million worth of grants from the National Institutes of Health to help further development of its drug pipeline. The Houston-based biopharmaceutical firm, a spin-off of the University of Texas Health Science Center, is working to create non-steroidal anti-inflammatory drugs that will have less serious gastrointestinal side effects than what’s currently out on the market. PLx's research has focused on ...
Click to read PLx Pharma gets $2M in NIH grants

Repros Therapeutics Inc. Reports First Quarter 2010 Financial Results
Print \| More options ▼ View RSS Feed
Release Date: 10-May-10 Author or Contact:
THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics (NasdaqCM: RPRX) today announced financial results for the first quarter ended March 31, 2010. Financial Results Net loss for the three month period ended March 31, 2010, was ($1.1) million or ($0.04) per share as compared to a net loss of ($6.8) million or ($0.45) per share for the same period in 2009. The decrease in loss for the three month period ended March 31, 2010 as ...
Click to read Repros Therapeutics Inc. Reports First Quarter 2010 Financial Results

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 First Quarter Results
Print \| More options ▼ View RSS Feed
Release Date: 10-May-10 Author or Contact:
THE WOODLANDS, Texas, May 10 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2010. "Achieving the remarkable results from our Phase 2a trial of LX4211 in patients with type 2 diabetes was the ...
Click to read Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 First Quarter Results

SEQUENCING OF FIRST FROG GENOME SHEDS LIGHT ON TREATING DISEASE
Print \| More options ▼ View RSS Feed
Release Date: 6-May-10 Author or Contact: Lisa Merkl
HOUSTON, May 6, 2010 – A pair of University of Houston researchers contributed to the assembly of the first comprehensive DNA sequence of an amphibian genome, which will shed light on the study of embryonic development, with implications for preventing birth defects and more effectively treating many human diseases. Amy Sater and Dan Wells, both professors in UH’s department of biology and biochemistry, collaborated with a ...
Click to read SEQUENCING OF FIRST FROG GENOME SHEDS LIGHT ON TREATING DISEASE

Stem cells: in search of a master controller
Print \| More options ▼ View RSS Feed
Release Date: 6-May-10 Author or Contact: Jade Boyd
HOUSTON -- (May 6, 2010) -- With thousands of scientists across the globe searching for ways to use adult stem cells to fight disease, there's a growing emphasis on finding the "master regulators" that guide the differentiation of stem cells. New research from Rice University and the University of Cambridge suggests that a closely connected trio of regulatory proteins fulfills that role in hematopoietic stem cells (HSCs), the self-renewing ...
Click to read Stem cells: in search of a master controller

Waste Management buys MedServe assets from Stericycle
Print \| More options ▼ View RSS Feed
Release Date: 6-May-10 Author or Contact: Sara Mathews
A Waste Management Inc. subsidiary has purchased certain assets of MedServe Inc., a medical waste management firm from its parent company, Stericycle Inc. WM Healthcare Solutions purchased MedServe’s Newton, Kan. autoclave treatment facility and its transfer stations in Kansas City, Mo., Oklahoma City, Omaha, Neb. and Booneville, Mo., for an undisclosed amount. The move was a condition of antitrust regulators before approving Lake ...
Click to read Waste Management buys MedServe assets from Stericycle

ArthroCare Corp. flips loss to net $8.8M in Q1 Read more: ArthroCare Corp. flips loss to net $8.8M in Q1 - Austin Business Journal:
Print \| More options ▼ View RSS Feed
Release Date: 6-May-10 Author or Contact:
Medical device maker ArthroCare Corp. (Nasdaq:ARTC) continued its rebound in the first quarter this year, turning $8.8 million net income on $90.6 million revenue, compared to a $6.5 million net loss on $78.8 million revenue the same quarter in 2009. The Austin company resumed trading on Nasdaq in January after it was delisted last year following an investigation that discovered transgressions and insurance billing irregularities. CEO ...
Click to read ArthroCare Corp. flips loss to net $8.8M in Q1 Read more: ArthroCare Corp. flips loss to net $8.8M in Q1 - Austin Business Journal:

OrthoAccel Technologies, Inc. and AB Orthodontics Announce Partnership and Australian Product Introduction
Print \| More options ▼ View RSS Feed
Release Date: 5-May-10 Author or Contact:
HOUSTON, May 5 /PRNewswire/ -- OrthoAccel Technologies, Inc. announced that it has entered into a partnership with AB Orthodontics, an Australian orthodontic supplies company, to introduce the AcceleDent System to the Australian market. AcceleDent, an acceleration device to enhance ...
Click to read OrthoAccel Technologies, Inc. and AB Orthodontics Announce Partnership and Australian Product Introduction

UH ENGINEERS TO IMPROVE TEST FOR CARDIOVASCULAR DISEASE
Print \| More options ▼ View RSS Feed
Release Date: 5-May-10 Author or Contact: Lisa Merkl
HOUSTON, May 5, 2010 – Two University of Houston professors are working to help keep your heart beating stronger and longer simply by monitoring the temperature of your fingertip. VENDYS, a device mechanical engineering professors Stanley Kleis and Ralph Metcalfe helped develop, is allowing doctors to monitor how changes in blood flow affect finger temperature to measure an individual’s risk for cardiovascular disease (CVD). ...
Click to read UH ENGINEERS TO IMPROVE TEST FOR CARDIOVASCULAR DISEASE

Endo Pharmaceuticals To Acquire HealthTronics To Expand Its Delivery of Diversified Urology Treatment and Diagnostic Solutions
Print \| More options ▼ View RSS Feed
Release Date: 5-May-10 Author or Contact:
Continuing to diversify, move into new growth areas beyond pharmaceuticals, and strengthen its commitment to improved patient outcomes in urology, Endo Pharmaceuticals (NASDAQ:ENDP) today announced that it has signed an agreement to acquire HealthTronics, Inc. (NASDAQ:HTRN) , a leading U.S. provider of urological products and services. The acquisition expands Endo's product offerings to urologists with the addition of lithotripsy, benign ...
Click to read Endo Pharmaceuticals To Acquire HealthTronics To Expand Its Delivery of Diversified Urology Treatment and Diagnostic Solutions

Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
Print \| More options ▼ View RSS Feed
Release Date: 5-May-10 Author or Contact:
THE WOODLANDS, Texas, May 5 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, presented results from its positive Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) at Digestive Disease Week (DDW) 2010 in New Orleans, Louisiana. LX1031 is an oral, serotonin ...
Click to read Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action

HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals
Print \| More options ▼ View RSS Feed
Release Date: 5-May-10 Author or Contact:
AUSTIN, Texas, May 5 /PRNewswire-FirstCall/ -- HealthTronics, Inc. (NASDAQ:HTRN) , a leading provider of urological products and services, today announced that it has signed a definitive merger agreement with Endo Pharmaceuticals (NASDAQ:ENDP) pursuant to which Endo will acquire HealthTronics. Under the terms of the merger agreement, Endo will commence an all cash tender offer to acquire all of the outstanding shares of HealthTronics common ...
Click to read HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals

ION Reports First Quarter 2010 Results
Print \| More options ▼ View RSS Feed
Release Date: 5-May-10 Author or Contact:
HOUSTON, May 5 /PRNewswire-FirstCall/ -- ION Geophysical Corporation (NYSE: IO) today reported first quarter 2010 revenues of $88.7 million, resulting in a net loss of ($11.2) million, or ($0.09) per share, excluding certain special items described below. In the first quarter of 2009, ION's net loss was ($10.4) million, or ($0.10) per share, on revenues of $106.9 million, excluding special items. During the first quarter of 2010, ION incurred ...
Click to read ION Reports First Quarter 2010 Results

Healthcare of Today Acquires Pharmaceutical Company Treating Dry Age-Related Macular Degeneration
Print \| More options ▼ View RSS Feed
Release Date: 4-May-10 Author or Contact:
BURBANK, CA -- May 4, 2010 -- Healthcare of Today, Inc. today announces that it has completed the acquisition of MacuCLEAR, Inc., a specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye. MacuCLEAR’s (www.macuclear.com) groundbreaking work leverages its unique understanding of ocular pharmacology and drug development to advance a pipeline of proprietary ...
Click to read Healthcare of Today Acquires Pharmaceutical Company Treating Dry Age-Related Macular Degeneration

MiddleBrook Pharmaceuticals Files for Chapter 11 Bankruptcy Protection
Print \| More options ▼ View RSS Feed
Release Date: 3-May-10 Author or Contact:
WESTLAKE, Texas--(EON: Enhanced Online News)--MiddleBrook Pharmaceuticals, Inc. (NASDAQ: MBRK) (“MiddleBrook” or the “Company”) has filed a voluntary petition (the “Petition”) for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”). MiddleBrook will continue to ...
Click to read MiddleBrook Pharmaceuticals Files for Chapter 11 Bankruptcy Protection

Repros: FDA may lift Proellex clinical hold
Print \| More options ▼ View RSS Feed
Release Date: 3-May-10 Author or Contact:
Repros Therapeutics (NASDAQ: RPRX) said today that following a teleconference with the FDA, the agency may be willing to lift the clinical hold status of Proellex if Repros can modify the study design. Clinical studies of the drug, which is under investigation for the treatment for uterine fibroids and endometriosis, were halted last year due liver enzymes changes at higher doses. Those changes were linked to serious adverse events. In early ...
Click to read Repros: FDA may lift Proellex clinical hold

Austin biopharmaceutical company wins $913K grant
Print \| More options ▼ View RSS Feed
Release Date: 29-Apr-10 Author or Contact:
Austin-based Selenium Ltd. was awarded a two-year, $912,943 grant from The National Institute of Dental and Craniofacial Research, officials announced Wednesday. The biopharmaceutical company, founded in 2004, is using the funds to develop antimicrobial dental devices and water line tubing. The company will receive $492,972 in the first research year and $419,971 when it achieves all year-one objectives. Selenium's SeLECT technology is ...
Click to read Austin biopharmaceutical company wins $913K grant

Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
Print \| More options ▼ View RSS Feed
Release Date: 29-Apr-10 Author or Contact:
The Woodlands, Texas, April 27, 2010 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that the company will be giving poster and oral presentations on results from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) at Digestive Disease Week (DDW) 2010 in New ...
Click to read Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week

The International Congress of Alzheimer's Disease Accepts Four Scientific Presentations by Power3 ( Power3 Presents NuroPro(R) to ICAD for the 2nd Year in a Row )
Print \| More options ▼ View RSS Feed
Release Date: 29-Apr-10 Author or Contact:
HOUSTON, Apr 28, 2010 (BUSINESS WIRE) -- Power3 Medical Products, Inc. ( OTCBB:PWRM -- News) announced that four abstracts were accepted for presentation to the annual meeting of the International Congress of Alzheimer's Disease on July 12, 2010 in Honolulu, Hawaii. The presentations will cover results from protein biomarker discovery, drug response, test development, and ongoing clinical validation trials of the NuroPro(R) AD biomarkers and ...
Click to read The International Congress of Alzheimer's Disease Accepts Four Scientific Presentations by Power3 ( Power3 Presents NuroPro(R) to ICAD for the 2nd Year in a Row )

[<< Prev] 1 2 3 4 5

Contact Us | Site Map |

| OPML | Search This Site | Home
Schipul Web Design | Houston Social Media | Tendenci� Content Management Software | Privacy | Terms and Conditions